# SODIUM DNA (sodium-dna) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/sodium-dna
- **Standard INCI**: `SODIUM DNA`
- **KR MFDS Standard Name**: `소듐디엔에이`
- **CAS No.**: `N/A`
- **EC / EINECS No.**: `N/A`
- **Origin**: `synthetic`
- **Functions**: 피부컨디셔닝제
- **Molecular Formula / MW**: `(Deoxyribonucleic acid sodium salt, 50~1,500 kDa)` (— g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 소듐디엔에이 |
| KR (Former Names) | — |
| EU (CosIng 1223/2009) | SODIUM DNA |
| US (PCPC / MoCRA INCI) | SODIUM DNA |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | DNA 钠 |
| JP (JCIA / MHLW QD) | ＤＮＡ－Ｎａ (QD: デオキシリボ核酸ナトリウム) |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `none`
- **EU (1223/2009)**: `none`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `allowed` (Entry: `383`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- **cn_iecic_max** (leave_on): ≤ 1% — NMPA IECIC (2025) Entry 08912 (2025)
- **cn_iecic_max** (rinse_off): ≤ 0.5% — NMPA IECIC (2025) Entry 08912 (2025)

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 5 – 7.5
- **Max Process Temp**: ≤ 50°C
- **Synergy Pairings**: HYDROLYZED SPONGE, SODIUM HYALURONATE, PANTHENOL, MADECASSOSIDE, NIACINAMIDE
- **Incompatibilities**: Susceptible to depurination and strand hydrolysis at pH < 4.0 or temperatures > 60°C; Forms insoluble complexes with cationic surfactants

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: SODIUM DNA | CAS No.: N/A | EC No.: N/A
  - Origin: SYNTHETIC | Functions: Skin Conditioning
  - Physicochemical Profile: Formula (Deoxyribonucleic acid sodium salt, 50~1,500 kDa) | MW /(Polymer/Complex) | /   | Ionic Nature: anionic | CosIng/MFDS 
  - Official Regional Label Names: US [SODIUM DNA] · EU [SODIUM DNA] · CN [DNA 钠] · JP [ＤＮＡ－Ｎａ] · JP Quasi-Drug [デオキシリボ核酸ナトリウム]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - Purified sodium salt of polydeoxyribonucleotide (PDRN, 50~1,500 kDa) acting as a selective Adenosine A2A receptor agonist. Downregulates pro-inflammatory cytokines (TNF-α, IL-6), upregulates VEGF and fibroblast proliferation, and supplies purine/pyrimidine bases via the nucleotide salvage pathway to accelerate tissue regeneration and dermal matrix repair.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 383 (DNA 钠))
  - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment).
  - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 1.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 0.5%
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - [aqueous_serum] Typical range: 0.01 ~ 1.0% (Median 0.2%, Ref: PubMed PDRN Dermatology Reviews & CN IECIC) — Adenosine A2A receptor agonist & tissue regeneration polynucleotide (PDRN)
  - [emulsion_cream] Typical range: 0.02 ~ 1.0% (Median 0.3%, Ref: PubMed Clinical Studies & CN IECIC) — Post-procedure skin recovery & dermal matrix repair active
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Cool-down Phase (< 45°C)
  - Optimal pH Range: pH 5.0 ~ 7.5 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM
  - Incompatibility / Caution: Susceptible to depurination and strand hydrolysis at pH < 4.0 or temperatures > 60°C
  - Incompatibility / Caution: Forms insoluble complexes with cationic surfactants
  - Synergy Pairings: HYDROLYZED SPONGE, SODIUM HYALURONATE, PANTHENOL, MADECASSOSIDE, NIACINAMIDE | Reference Trade Names: PDRN®, c-PDRN®, Vegan Phyto-PDRN
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - Validated against official regulatory compendia (MFDS/CosIng/CIR/SCCS) and physicochemical standards.

## 6. Linked PubMed Literature